Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1370053 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $52.14Day +0.06%Mkt cap $1.5B1Y +198.3%Off 52W high −27.9%Vol (1Y) 74.0%
Daily closing price, split-adjusted to the current basis; 3y shown of 2,386 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest17.2% of sh out |
| Days to cover5.9d |
| 13F net flow (QoQ)−6.06% |
| Top-10 13F concentration59.3% |
| Next report (est.)2026-08-10 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$232.4M |
| Earnings (TTM)-$26.8M |
| ROE−24.5% |
| Net margin−5.6% |
| Sales growth 3Y183.6% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+61.3% |
| 1Y+198.3% |
| 3Y+296.8% |
| 5Y+233.5% |
| Since incept. (ann.)+17.4% |
Total return through 2026-07-29 · series begins 2017-01-26. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)74.0% |
| Ann. volatility (3Y)73.2% |
| Sharpe (1Y)1.84 |
| Sharpe (3Y)1.07 |
| Max drawdown (1Y)−28.0% |
| Max drawdown (3Y)−69.3% |
| Beta (3Y vs SPY)2.15 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 7.9M | $437M | 27.41% | +0.0% |
| BlackRock, Inc. | 1.7M | $93M | 5.85% | −3.1% |
| TANG CAPITAL MANAGEMENT LLC | 1.3M | $74M | 4.63% | −0.1% |
| MORGAN STANLEY | 993,905 | $55M | 3.46% | −3.9% |
| STATE STREET CORP | 992,445 | $55M | 3.45% | −5.8% |
| Affinity Asset Advisors, LLC | 940,000 | $52M | 3.27% | +111.4% |
| VANGUARD CAPITAL MANAGEMENT LLC | 853,151 | $47M | 2.97% | new |
| Palo Alto Investors LP | 638,161 | $35M | 2.22% | −7.5% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-12 | −$1.84 | — | $25.6M | −8.0% |
| 2025-12-31 | 2026-03-03 | — | — | $108.2M | +151.1% |
| 2025-09-30 | 2025-11-04 | $0.52 | — | $76.3M | +154.3% |
| 2025-06-30 | 2025-08-06 | −$1.34 | — | $22.3M | +102.9% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-10 is ESTIMATED from filing cadence (median gap 90d) — not company-confirmed.
Royalty Management Company 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
